The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.

The U.S. Food and Drug Administration (FDA ) leaders said on Tuesday they would adopt a new COVID-19 vaccination regulatory ...

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...